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Abstract
Migraine is a common neurological disorder characterized by nausea, vomiting, photophobia, aching, fever, pain and chills. Triptans are selective serotonin agonists
which can used to relieve migraine symptoms. Almotriptan malate and naratriptan hydrochloride are currently used for the management of migraine in the form
of oral tablets. Oral tablets may be problematic for patients experiencing nausea and vomiting which are often associated with migraine. The microneedle-assisted
transdermal drug delivery of these triptans may improve patient compliance. A vertical six-celled, static Franz diffusion cell system was used to conduct in vitro
permeation experiments on porcine ear skin to determine the influence of microneedle-assisted transdermal delivery of both almotriptan malate and naratriptan
hydrochloride. HPLC-MS analysis was performed using an Agilent 1200 series high performance liquid chromatography system in combination with an Agilent
time of flight mass spectrometer (TOF-MS) system model 6230 (Agilent, Santa Clara, CA, USA). A reversed phase liquid chromatography column (Agilent Zorbax
Eclipse Plus C18, 100 mm X 2.1 mm, 3.5 µm), was utilized for chromatographic separation. Confocal laser scanning microscopy was used to characterize the depth
of the microchannels created after stainless-steel microneedle roller application. Transdermal flux of both triptans was calculated from the linear portion of the
cumulative amount of drug permeated versus time curve. The mean passive flux of almotriptan malate was 13.044 ± 0.32 µg.cm2.h, while the mean flux following
microneedle roller application was 11.281 ± 0.22 µg.cm2.h. The mean flux values for naratriptan hydrochloride for passive and after microneedle roller application was
0.88 ± 0.29 µg.cm2.h and 4.18 ± 1.39 µg.cm2.h, respectively. Statistical analysis was performed using the Student’s t-test (GradPad Prism 7). A statistically significant
difference (p<0.05) between microneedle-treated porcine skin samples compared to untreated skin samples was found for the transdermal flux values of naratriptan
hydrochloride. Solid stainless-steel microneedle rollers enhanced the transdermal delivery of naratriptan hydrochloride. In contrast, transdermal flux values obtained
for almotriptan malate indicate that differences between microneedle-treated and untreated skin samples was not statistically significant (p>0.05).

Introduction
Migraine is a common neurological disorder that affects
numerous individuals nationwide [1]. Females are three times more
likely to suffer from migraine in comparison with males and the
disorder is more prevalent in individuals between the ages of 25 and
55 years [2,3]. Symptoms of migraine include: nausea, vomiting,
photophobia, aching, fever and chills. Migraines are usually due to
cranial vasodilation and/or the release of pro-inflammatory sensory
neuropeptides from the trigeminal system [4]. Although not much
is known about the etiology of migraine current studies indicate that
the pathophysiology of the disorder maybe linked with both neural
and vascular mechanisms. Activation of the trigeminovascular system
triggers the release of vasodilators which contribute to the headache
associated during a migraine [4]. Vasoactive neuropeptides induce
vasodilation and are located within the trigeminal neurons. Vasoactive
neuropeptides mediating vasodilation include: calcitonin gene-related
peptide (CGRP), substance P, and neurokinin A [5]. CGRP is the
most critical neuropeptide involved in the generation of migraine [4].
The release of vasoactive neuropeptides from the trigeminal nerve
terminals induces inflammatory reactions in the meningeal blood
vessels [4]. Further, the association of 5-hydroxytrptamine (5-HT)
and migraine pathophysiology is supported by the increasing levels
of 5-hydroxyindoleacetic acid, a major metabolite of 5-HT, during a
migraine [5].
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Increased understanding of the role 5-HT receptors play in regard
to migraine has led to the development of new medications such as
triptans. Triptans are serotonin 5-HT 1B and 1D receptor agonists
and can be used to for the management of migraine [5]. Triptans work
by binding to selective serotonin receptors like the 5-HT 1B and 1D
receptors [5]. The 5-HT 1B receptors are located in the intracranial
blood vessels within smooth muscle cells while the 5-HT 1D receptor
is expressed in the trigeminal nerve fibers [4]. The activation of these
receptors is believed to produce cranial vasoconstriction and provide
pain relief [5]. Triptans have three modes of action which contribute to
their anti-migraine effects [6]. These effects include: vasoconstriction of
intracranial extracerebral vessels, inhibition of vasoactive neuropeptide
release by the trigeminal terminals, and nociceptive neurotransmission
inhibition [6].
Triptans are commonly available as tablets for oral administration
[7]. However, many migraine patients fail to comply with oral
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triptans because oral treatments may be ineffectual for patients who
are experiencing nausea, vomiting, and gastric-stasis which are often
associated with migraine [6]. This will interfere with the oral drug
absorption and even delay the initial use of the oral medication [7].
Due to the limitations of oral triptans transdermal drug delivery
will be a more viable option [7]. The long-term goal is to develop a
microneedle-assisted transdermal system for the delivery of both
triptans: almotriptan malate and naratriptan hydrochloride.

which relieves the pain associated with a migraine [2]. Similar to other
triptans, almotriptan malate induces vasoconstriction by acting on the
5-HT 1B receptors and inhibits nociceptive transmission by activating
the 5-HT 1D receptors [3]. Almotriptan malate’s effect on nociceptive
transmission contributes to the efficacy on pain transmission, but also
its effect in improving associated symptoms such as including nausea,
vomiting, or photophobia [3]. A transdermal delivery system for
almotriptan malate may provide benefits that oral dosage forms do not.

There are several advantages of transdermal drug delivery which
include: avoidance of gastrointestinal irritation, prevention of the firstpass effect, and the provision of stable drug plasma concentration over
a sustained period of time [5]. In addition, transdermal delivery also
provides a pain-free mode of drug administration. However, not all
drugs are suitable for transdermal delivery [8]. For a drug to cross the
skin barrier and be delivered into the bloodstream, it must have certain
physicochemical properties such as low molecular weight, optimal
partition and diffusion coefficients, including appropriate temperature
and pH [9]. The greatest drawback of transdermal delivery systems is
the poor permeability through the stratum corneum [10].

Naratriptan hydrochloride is another triptan drug utilized for
the treatment of migraines. The brand name is Amerge and it has the
molecular weight of 335.464 g/mol [17]. This triptan acts as a selective
agonist for 5-HT 1B and 5-HT 1D receptors involved in mediating
vascular constriction which provides pain relief from migraine
[2]. Activation of the 5-HT 1B and 5-HT 1D receptors located in
the sensory nerves of the trigeminal system results in the inhibition
of vasoactive neuropeptide release which helps to relieve migraine
symptoms [2]. Naratriptan hydrochloride is well absorbed, with a 74%
oral bioavailability and has a long half-life of approximately six hours
[7]. This triptan may help improve patient compliance if constructed
into a transdermal patch.

The stratum corneum (SC) is the main penetration barrier in
transdermal drug delivery [10]. It is the outermost layer of the epidermis
and consists of 15-20 layers of corneocytes which are embedded
in a lipid matrix [10,11]. The aqueous pores in the hydrophilic
regions of the SC help to facilitate the transcutaneous diffusion of
penetrants [12]. There are several ways of overcoming the SC barrier
including sonophoresis, iontophoresis, prodrugs, microemulsions and
microneedles (MN) [10,13].
MNs are micron-sized needles that can facilitate the skin
penetration of medications by creating micropores which increase
transdermal diffusion of drugs [14]. The application of MN allows for
painless penetration of the SC barrier which is appealing to patients
with needle-phobias because MN does not stimulate the nerves
associated with pain [11]. A common disadvantage of MN is that only
small amount of the drug can be given each time of administration
compared to when using hypodermic needles. MN have been fabricated
in a range of different sizes, shapes, and materials [8]. There are five
different types of MN which include: solid, coated, dissolving, hollow,
and hydrogel-forming [10,11,15]. When using solid MN the drug is
applied to the skin after creating micro-pores across the skin [11,13].
MN can also be coated with the drug, where the drug is dissolved off
and then the MN are removed [11]. MN can be completely dissolving
into the skin where the drug is encapsulated within microneedle and
released upon insertion into skin [11]. Alternatively, hollow MN can be
used to inject liquid drugs into the skin through a needle bore [11,13].
Hydrogel-forming MN facilitate drug delivery by controlled swelling
of the MN patch arrays and upon swelling the drug is released [13].
We will be using solid microneedles for the transdermal delivery of
almotriptan malate and naratriptan hydrochloride across porcine
ear skin. Microneedle-assisted transdermal delivery can potentially
enhance the skin permeability for drug compounds and may lead to
a statistically significant increase in transdermal flux values for both
almotriptan malate and naratriptan hydrochloride.
Almotriptan malate is a sulfonamide triptan which has shown to
be effective in treating migraines with or without aura [2]. It is sold
under the brand name Axert and has the molecular weight of 333.465
g/mol [16]. Almotriptan malate selectively binds to and activates
serotonin 5-HT 1B and 1D receptors, which are localized in the central
nervous system [6]. This triggers intracranial blood vessel constriction
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Porcine ear skin was used as a substitute for human skin due to
similar skin properties. The SC thickness for porcine at 21-25 µm is
comparable to the SC thickness for human skin at 10-25 µm [1820]. Density of hair follicles between porcine skin and human
skin was 20/cm2 and 14-32/cm2, respectively [19,21]. Porcine skin
is inexpensive and has shown prior reliability for in-vitro skin
permeation studies [22].
The influence of stainless-steel microneedle rollers on the
transdermal delivery of almotriptan malate and naratriptan
hydrochloride across pig ear skin in-vitro was studied. It was
hypothesized that microneedle-assisted delivery of both triptans will
enhance the transdermal flux.

Materials and Methods
Materials
Almotriptan malate, naratriptan hydrochloride, phosphate buffer
saline (PBS, pH 7.4) were purchased from Sigma Aldrich Co. (St. Louis,
MO, USA). PBS was used as a reconstitution agent for almotriptan
malate and naratriptan hydrochloride. The NanoPure Infinity
Ultrapure water system (Barnstead, Dubuque, IA, USA) was used to
obtain deionized water for all experiments. Stainless-steel microneedle
rollers with a density of 192 microneedles and microneedle length of
500 µm were obtained from Pearl Enterprises LLC (Lakewood, NJ
USA). Raw porcine ears were purchased from Pel- Freez Arkansas LLC
(Rogers, AR, USA) and allowed to thaw at room temperature before
experimental use.

Methods
Skin Preparation: The Institutional Animal Care and Use
Committee (IACUC) and Institutional Biosafety Committee (IBC)
of Touro University, Mare Island-Vallejo, CA, USA approved the
experiments. Raw porcine ears were purchased, thawed and carefully
shaved using an electric hair clipper. An electric dermatome was
utilized (Nouvag®, Goldach, Switzerland) to prepare split-thickness
skins and the Digimatic Micrometer (Mitutoyo, Tokyo, Japan) was
used to measure the thickness of the porcine samples. The dermatomed
skin samples obtained were individually enclosed in aluminum foil and
plastic bags and stored at -20 °C until further use.
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In-vitro Diffusion Studies: A vertical six-celled Franz diffusion
system (PermeGear, Hellertown, PA, USA) was utilized to conduct
transdermal permeation studies. The six cells consisted of a top donor
compartments and lower receptor compartments. To help maintain
uniform drug distribution the receptor cells were magnetically
stirred. Each of the six cells also consisted of a sampling port and a
circulating water jacket at 37 °C to simulate human body temperature
(ThermoFisher Scientific, Waltham, MA, USA). The Franz diffusion
cells had a diffusion area of 1.77cm2 a receptor volume of 12mL filled
with PBS.
Microneedle-treated and untreated porcine ear skin samples were
used for this experiment. To prepare microneedle-treated samples
a stainless-steel microneedle roller was applied to porcine skins to
create microchannels. To create microchannels in the skin samples
the microneedle roller was applied 15 times to each skin sample
in the vertical, diagonal, and horizontal directions. The roller was
applied and measured at a force of 20lbs using a weighing scale. Three
of six compartments of the Franz diffusion cell system contained
microneedle treated skin samples while the remaining three consisted
of untreated samples, serving as controls. Porcine ear skins were
mounted between the upper donor and lower receptor compartments.
Vacuum grease was utilized (Dow Corning, Midland, MA, USA) along
with a metal clamp to help hold the porcine samples stay in place and
prevent loss of triptan solution. Skin samples were placed with the
stratum corneum surface facing towards the donor cell. Diffusion
experiments for both triptans were replicated six times each (n=6) and
each experiment was conducted out using 1 mL of either almotriptan
malate or naratriptan hydrochloride. The triptan was placed on porcine
skin samples using 1 mL syringes through the donor compartment. To
help reduce evaporation the donor compartments and sampling ports
were covered with parafilm and aluminum foil. At intervals of 2 hours
for a 12-hour period, 1mL aliquots of the receptor solution were taken
using 1 mL syringes. Collected solutions were placed in vials from
Agilent Technologies (Agilent, Santa Clara, CA) and stored in 4°C
until shipment to the University of Idaho for high performance liquid
chromatography-mass spectrometry (HPLC–MS) analysis. After each
extraction receptor compartments were refilled with an equal volume
of fresh PBS (1mL). Using the collected HPLC-MS data the cumulative
amount of drug permeated was plotted as a function of time for
both triptans. The slope of the steady state portion of the cumulative
amount of drug permeated over time was used to further calculate the
transdermal flux values.
HPLC/DAD/TOF-MS Analysis of Pharmaceuticals: Quantitative
analysis of the drug concentrations in the samples collected was carried
out using HPLC-MS analysis. HPLC-MS analysis was performed using
an Agilent 1200 series liquid chromatography system in combination
with an Agilent time of flight mass spectrometer (TOF-MS) model
6230 (Agilent, Santa Clara, CA, USA). Chromatographic separation
was achieved using a reversed phase liquid chromatography column
(Agilent Zorbax Eclipse Plus C18, 100 mm X 2.1 mm, 3.5 µm) with
temperatures maintained at 30°C (Agilent, Santa Clara, CA, USA). The
mobile phase consisted of 0.1% formic acid in acetonitrile. From 3 to
20% there was a linear gradient in 3 min followed by an increase to
100% in 2 min. Equilibration at 3% was subsequently carried out for
5 min. The mobile phase flow rate was 0.3 mL min-1 with an injection
volume of 5 µL. The reconstructed ion current mode with a m/z of
336.16 was used to perform quantification of both triptans.
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Microchannel Depth Characterization by Confocal Laser
Scanning Microscopy (CLSM): CLSM was performed at the Van
Winkle Lab housed in the Center for Health and the Environment
of the University of California, Davis to characterize the depth of
the microchannels created by the stainless-steel microneedle roller.
Confocal images were taken of both microneedle-treated and untreated
skin samples. After the microneedle roller application, porcine samples
were treated with 200 uL of fluorescent dye, Alexaflour 594 (Thermo
Fisher Scientific, Waltham, MA, USA). The sample was then blotted
with Kimwipes (Kimberly-Clark Professional, Roswell, GA, USA) to
remove excess dye. Strips of microneedle-treated porcine skin were
cut into sections, embedded with OCT medium (Sakura Finetek Inc.,
Torrance, CA, USA) and placed onto Tissue-Tek Cryomolds (Sakura
Finetek Inc., Torrance, CA, USA). All samples were cryosectioned to
10 µm thick vertical sections using a Leica CM1950 Cryostat (Leica
Biosystems, Buffalo Grove, IL, USA) and transferred onto glass slides
in preparation for CLSM. Confocal images of microneedle-treated and
untreated skin samples taken using a Leica TCS LSI laser scanning
confocal microscope. The frame was set at 1024 X 1024 pixels with a
magnification of 5X. Excitation was carried out at 590 nm and emission
at 617 nm. Untreated porcine samples were also treated with Alexaflour
594, cryosectioned and examined using the Leica TCS LSI confocal
laser scanning microscope.
Data Analysis: The transdermal flux of both triptans was
determined from the slope of the average cumulative amount versus
time curve. For each drug experiments were replicated six times and
the dilution of each drug was accounted for by using the Hayton-Chen
equation.
 VT  Cn1−1 
Cn1 = Cn 


 VT − VS  Cn −1 

For the Hayton–Chen equation,
is the corrected concentration
and Cn is the measured concentration in the nth sample. VT stands for
the total volume of the receptor fluid (12 mL) and VS is the volume of
sample withdrawn from the receptor fluid (1 mL). Cn1−1 represents the
corrected concentration in (n-1)th sample while Cn −1 is the measured
concentration in (n-1)th sample.
Statistical Analysis: GraphPad Prism 7 (GraphPad Software, Inc.,
La Jolla, CA, USA) was used to perform statistical analysis. Results with
a p-value of less than 0.05 was considered to be statistically significant.
To plot the graphs, the average replicates (n=6) with corresponding
standard deviation was used for both almotriptan malate and
naratriptan hydrochloride (Table 1).

Results
Microchannel Formation
Confocal laser scanning microscopy was used to compare both
microneedle-treated and untreated skins. Untreated porcine skin
samples were used as controls to compare against microneedle-treated
Table 1. Transdermal flux (µg/cm2/h ± SD) of naratriptan hydrochloride and almotriptan
malate following microneedle roller application. Passive flux values served as controls (n = 6)
Solution Name

Passive (µg/cm2/h)

Microneedle (µg/
cm2/h)

P- Value

Naratriptan
hydrochloride

0.881 ± 0.293

4.187 ± 1.396

0.0054

Almotriptan malate

13.044 ± 0.32

11.281 ± 0.22

0.6053
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samples and determine whether microchannels were formed after
microneedle roller application. Figure 1A shows the formation of a
microchannel after being treated with microneedle rollers. It is visible
that the microneedle roller successfully penetrated the stratum corneum
to create micropores in the skin which were visible with Alexaflour
594 fluorescent dye. The pore constructed by the microneedle roller is
displayed in Figure 1A with a microchannel depth of 215 µm. Unlike
Figure 1A, the untreated porcine skin displayed in Figure 1B displays
no microchannels.

In-vitro Diffusion Study
Transdermal flux of both naratriptan hydrochloride and almotriptan
malate was calculated from the linear portion of the cumulative amount
versus time curve. The flux for naratriptan hydrochloride across
microneedle-treated pig skin was 4.18 ± 1.39 µg.cm2.h while the flux
for passive diffusion was 0.88 ± 0.29 µg.cm2.h. There was a statistically
significant difference (p<0.05) in the transdermal flux values of
naratriptan hydrochloride across microneedle-treated porcine samples
compared to passive diffusion. Passive penetration rates for naratriptan
hydrochloride were low compared to microneedle therefore solid
stainless-steel microneedles enhanced the transdermal delivery of this
drug. Meanwhile, for the permeation profile of almotriptan malate
there was not a statistically significant difference between microneedletreated and untreated samples. The passive and microneedle-treated
flux obtained for almotriptan malate was 13.044 ± 0.32 and 11.281 ±
0.22, respectively (Figure 2).

Discussion
In this paper, the effect of microneedles on the percutaneous
transport of almotriptan malate and naratriptan hydrochloride were
investigated. Microchannel visualization with confocal microscopy
confirmed that the microneedle roller was successfully able to
penetrate the skin. Banga, et al. reported that the application of a
microneedle roller creates microchannels in the skin allowing for
enhanced transdermal drug delivery [23]. Methylene blue staining
and histological sectioning were used to confirm microchannels
while confocal laser scanning microscopy was used to characterize
microchannel depth after microneedle roller application [23]. In our
project, confocal microscopy images confirmed that the stainless-steel
microneedle roller was capable of overcoming the skin barrier to create
microchannels across porcine skin [24]. Confocal images comparing
microneedle-treated and untreated skin samples indicate that
microchannels were created following the application of a microneedle
roller (Figure 3). However, despite microchannel formation there was
no statistically significant increase in the percutaneous absorption for
almotriptan malate. The difference between microneedle-treated
and passive flux values of almotriptan malate was not statistically
significant (p<0.05).
Triptans are commonly taken orally in the form of tablets. Patients
with chronic migraine take medications more than once a day [7].

A

B

Figure 1. Chemical structures of (A) almotriptan malate and (B) naratriptan hydrochloride
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Figure 2. Stainless-steel microneedle roller with microneedles 500 µm in length and
density of 192 needles

Almotriptan malate is available in 6.25mg tablets with a maximum
daily dosage of 25mg while naratriptan hydrochloride tablets are
available in 1mg or 2.5mg tablets with a maximum daily dosage of
5mg [7]. However, due to the symptoms associated with migraine
such as pain, vomiting, and nausea many times patients are unable
to ingest tablets orally. Other disadvantages include the presystemic
metabolism, degradation by enzymes and acid in the stomach, and
erratic absorption [8]. Therefore, a microneedle transdermal delivery
system would be useful in improving patient compliance. Arya et al.
also tested dissolving microneedle patches on human subjects and
found that the patches were well tolerated with no pain and swelling,
and self-administration rates of microneedle patches were high [25]. A
larger phase 1 clinical study conducted on 100 human subjects tested
the efficacy of dissolving microneedles to deliver influenza [26]. It was
found that the found that vaccine delivery using a microneedle patch
was similar to that of when using a hypodermic needle [26]. Needlephobia is a challenge with many patients and having a microneedle patch
would be would be beneficial. Arya et al. also reported that the microneedle
patch was preferred by patients over a hypodermic needle [25].
For almotriptan malate, the difference in flux values between
microneedle-treated and passive was not statistically significant
(p<0.05). Several factors may have impacted this occurrence. The
effectiveness of a microneedle-assisted transdermal delivery system
is dependent on the properties of the skin, the microneedles, and the
drug. Since drug entry is imposed by skin permeability the interaction
of a specific drug and the skin varies; this is an important factor to
be considered. Physiochemical properties of the compound such as
molecular weight, drug concentration, pH, melting point, and partition
coefficient all influence the rate of transdermal drug delivery. Small
molecular weight compounds penetrate at a faster rate that larger ones,
therefore having a molecular weight of less than 500 Daltons is typically
needed to cross the stratum corneum. The human skin consists of a
lipid rich bilayer which makes it necessary for compounds to have
both aqueous and lipid solubilities. An ideal transdermal drug delivery
candidate would have an aqueous solubility of greater than 1 mg/
mL, partition coefficient (log P) between 1-3, point of less than 200
°C [27]. Compounds with log P values below 1 are too hydrophilic to
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A

B

Figure 3. Images of porcine skin samples by confocal laser scanning microscopy (CLSM). (A) Microneedle treated porcine skin showing a single microchannel depth of 215 μm (B)
Untreated porcine skin

effectively disrupt the stratum corneum while those greater than 3 are
too hydrophobic resulting in low therapeutic plasma concentrations
[27]. The melting point of a compound is indirectly proportional to
its lipophilicity and solubility in skin lipids [13]. A low melting point
will allow for faster penetration and optimal transdermal delivery.
Almotriptan malate has a molecular weight of 335.466 Daltons,
log P value of 1.6, and a melting point of 170 °C [7]. However, the
interactions between the drug, microneedles and the skin are complex.
Several investigators have studied the relationship between the
physicochemical properties of compounds and skin permeability
[28,29]. Only a few variables were studied in the Potts-Guy equation
but currently those variables now include properties such as dipole
moment and polar surface area [28,29]. Clearly, these are complex
interactions worthy of further investigation (Figures 4 and 5)
Microneedle length, density, insertion force and time can all
influence the permeation rates of compounds across the skin. A
possible explanation of why there was low flux values for microneedletreated skin samples for almotriptan malate maybe dependent on
microneedle length and density. Microneedles that were 500 μm in
length were used for this study. Increasing the length may increase
the penetration rate of almotriptan malate. In the study by Nalluri, et
al. 500 μm and 1000 μm microneedles were compared for the in vitro
permeation of Levodopa across porcine ear skin [30]. It was found that
longer microneedle arrays are able to create pores at a greater [30]. The
use of 500 μm microneedle arrays led to a lower permeation rate of
levodopa probably due to the inability of the shorter microneedles to
create deep enough pores [30]. Another study by Li, et al. reported that
the microneedle-assisted transdermal delivery effectively increased
antibody delivery when microneedle length, microneedle array, and
drug concentration were increased [31]. Banga, et al. confirmed that
an increase in microneedle length from 500 μm to 1100 μm and 1400
μm enhanced microchannel depth [14]. A greater microneedle depth is
sometimes associated with increased drug penetration [14]. The results
showed that an increase in needle length from 500 μm to 1100 μm and
1400 μm significantly increased microchannel depth in the skin [24]. It
is important to consider these factors for future studies as this may assist
in enhancing the delivery of almotriptan malate. The study conducted
by Calatayud-Pascul, et al. confirmed that therapeutic drug levels for
almotriptan were obtained using an iontophoresis transdermal delivery
system [32]. Iontophoresis uses an electrical current to increase drug
penetration through the skin [32]. For iontophoresis, a compound
less than 12,000 Daltons can be successfully delivered across the skin
whereas for microneedle transdermal drug delivery and ideal candidate
must have a much lower molecular weight [13]. Using iontophoresis
in combination with microneedles has shown to results in faster drug
delivery and permeation rates due to both the micropores creates and
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Figure 4. In-vitro cumulative amount versus time curve of naratriptan hydrochloride across
microneedle-treated and untreated porcine ear skin over 12 hours

Figure 5. Transdermal flux of naratriptan hydrochloride across microneedle-treated and
untreated porcine ear skin over 12 hours

the electrical current pushing the drug into the skin [33]. Possibly
increasing the concentration of almotriptan malate can enhance
transdermal permeation however that is again limited because of the
need for a low molecular weight when using microneedles. Sachdeva
et al. found that iontophoresis treatment delivered three times more
drug concentration compared to microneedle treatment [33]. The
combination of enhancement technologies such as microneedles with
iontophoresis may prove to be effective for the transdermal delivery of
almotriptan malate.
Furthermore, the low flux levels of almotriptan hydrochloride
across microneedle-treated skin samples may have resulted from
the “bed of nails” effect. The phenomenon is associated with high
microneedle density and close needle-to-needle spacing which reduces
the penetration and efficiency of microneedles [34,35]. Yan, et al.
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studied microneedles densities ranging from 400 to 11,900 needles/
cm2 [36] . Exerting the same force on the microneedle arrays, the study
found that arrays with less than 2000 needles/cm2 increased drug flux
greater than higher needle density arrays of 5625 needles/cm2 [36]. It
has been observed that when microneedle density is high the pressure
exerted by each microneedle is significantly reduced preventing proper
penetration [34]. Applying the same force to a microneedle array of
lower density may have allowed for a greater enhancement of drug flux.
Unlike almotriptan malate, skin pretreatment with microneedle
rollers helped to enhance transdermal permeation for naratriptan
malate. The molecular weight of naratriptan hydrochloride is 371.924
Daltons, it has a log P value is 1.6, and melting point is 246 °C [7].
This indicates that significant amounts of naratriptan hydrochloride
can be delivered through the skin barrier with microneedles in
comparison to passive permeation. Further in-vitro studies are needed
to determine the influence of variables such as drug concentration,
microneedle length, density and design, on the transdermal flux of
these triptans. Solid stainless-steel microneedle rollers were used for
this experiment. Therefore, it would be interesting to compare flux
enhancement with different types of microneedles for almotriptan
malate transdermal delivery instead of solely using solid microneedle
rollers. The combination of microneedles with other techniques such
as iontophoresis and sonophoresis may help enhance permeation rates.
Future in-vivo studies should be performed to test for the efficiency of a
microneedle-assisted transdermal system for both triptans: almotriptan
malate and naratriptan hydrochloride (Figures 6 and 7)

Conclusion
This research was carried out to study the influence of
microneedles on the transdermal delivery of almotriptan malate and
naratriptan hydrochloride. For naratriptan differences in flux values
of microneedle-treated and untreated porcine skin samples using
solid microneedles were statistically significant (p<0.05). Conversely,
for almotriptan malate there was not a statistically significant increase
in transdermal flux across porcine skin following the application of a
microneedle roller (p>0.05).
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